
中华生物/人呼吸道合胞病毒(RSV)(A2)融合糖蛋白/RSV-F蛋白(ECD,His-Tag)/1/11049-V08B
商品编号:
11049-V08B
品牌:
sinobiological
市场价:
¥0.00
美元价:
0.00
联系Q Q:
3392242852
电话号码:
4000-520-616
电子邮箱:
info@ebiomall.com
商品介绍
Human respiratory syncytial virus (RSV) (A2) Fusion glycoprotein / RSV-F Protein (ECD, His Tag): Product Information
Purity
> 95 % as determined by SDS-PAGE
Endotoxin
< 1.0="" eu="" per="" μg="" of="" the="" protein="" as="" determined="" by="" the="" lal="">
Activity
Testing in progress
Protein Construction
A DNA sequence encoding the extracellular domain of human RSV Fusion glycoprotein (P03420.1) (Met1-Thr529) was expressed fused with a polyhistidine tag at the C-terminus.
Accession#
P03420.1
Expressed Host
Baculovirus-Insect Cells
Species
RSV
Predicted N Terminal
Gln 26
Molecule Mass
The secreted recombinant human RSV-F comprises 514 amino acids with a predicted molecular mass of 57.4 kDa. The RSV F0 precursor protein is cleaved into the disulfide-linked F1 and F2 subunits. As a result of glycosylation, the apparent molecular mass of the protein is approximately 45-55 kDa and 18 kDa in SDS-PAGE under reducing conditions, corresponding to the two subunits respectively.
Formulation
Lyophilized from sterile 50mM Tris, 100mM NaCl, pH 8.0, 10% glycerolPlease contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
Human respiratory syncytial virus (RSV) (A2) Fusion glycoprotein / RSV-F Protein (ECD, His Tag): Images

Human respiratory syncytial virus (RSV) (A2) Fusion glycoprotein / RSV-F Protein (ECD, His Tag): Synonyms
F Protein, RSV; HRSVgp08 Protein, RSV
RSV Fusion Background Information
Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. It is classified within the genus pneumovirus of the family paramyxoviridae. Like other members of the family, HRSV has two major surface glycoproteins (G and F) that play important roles in the initial stages of the infectious cycle. The G protein mediates attachment of the virus to cell surface receptors, while the F protein promotes fusion of the viral and cellular membranes, allowing entry of the virus ribonucleoprotein into the cell cytoplasm. The fusion (F) protein of RSV is synthesized as a nonfusogenic precursor protein (F), which during its migration to the cell surface is activated by cleavage into the disulfide-linked F1 and F2 subunits. This fusion is pH independent and occurs directly at the outer cell membrane, and the F2 subunit was identifed as the major determinant of RSV host cell specificity. The trimer of F1-F2 interacts with glycoprotein G at the virion surface. Upon binding of G to heparan sulfate, the hydrophobic fusion peptide is unmasked and induces the fusion between host cell and virion membranes. Notably, RSV fusion protein is unique in that it is able to interact directly with heparan sulfate and therefore is sufficient for virus infection. Furthermore, the fusion protein is also able to trigger p53-dependent apoptosis.
References
- Martin-Gallardo A. et al., 1993, J Gen Virol. 74 (3): 453-8.
- Jose A M. et al., 1997, J Gen Virol. 78: 2411-8.
- Feldman SA. et al., 1999, J Virol. 73 (8): 6610-7.
- Zlateva K.T. et al., 2004, J Virol. 78 (9): 4675-83.
- Trento A. et al., 2006, J Virol. 80 (2): 975-84.
- Branigan P J. et al., 2006, J Gen Virol. 87 (2): 395-8.
- Eckardt-Michel J. et al., 2008, J. Virol. 82: 3236-49.
RSV RSV Fusion Proteins
- Human respiratory syncytial virus (RSV) Fusion Recombinant (aa 1-526, His Tag)40627-V08B
- Human respiratory syncytial virus (RSV) Fusion Recombinant (aa 1-525, His Tag)40628-V08B
- Human respiratory syncytial virus (RSV) Fusion protein / RSV-F (Strain RSS-2) Protein (His Tag)40037-V08B
- Intranasal immunization with W 80 5EC adjuvanted recombinant RSV rF-ptn enhances clearance of respiratory syncytial virus in a mouse model.AuthorPassmore C, Makidon PE, O"Konek JJ, Zahn JA, Pannu J, Hamouda T, Bitko V, Myc A, Lukacs NW, Fattom A, Baker JR Jr1.Year2013JournalHuman Vaccines & ImmunotherapeuticsApplicationsubunit vaccinePubMed ID: 24326268FoldedExpand
- Development of an intradermal DNA vaccine delivery strategy to achieve single-dose immunity against respiratory syncytial virusAuthorSmith, TRF;Schultheis, K;Morrow, MP;Kraynyak, KA;McCoy, JR;Yim, KC;Muthumani, K;Humeau, L;Weiner, DB;Sardesai, NY;Broderick, KE;Year2017JournalVaccineApplicationELISA(as coating antigen)PubMed ID: 28413132FoldedExpand
- A rapid and quantitative technique for assessing IgG monomeric purity, calibrated with the NISTmAb reference materialAuthorReader, PP;Olkhov, RV;Reeksting, S;Lubben, A;Hyde, CJ;Shaw, AM;Year2019JournalAnal Bioanal ChemApplicationbindingPubMed ID: 31375854FoldedExpand
- Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen MicroarrayAuthorDe Assis, RR;Jain, A;Nakajima, R;Jasinskas, A;Year2020JournalBioRxivFoldedExpand
- Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen MicroarrayAuthorKhan, S;Nakajima, R;Jain, A;De Assis, RR;Jasinskas, A;Year2020JournalBioRxivFoldedExpand
- Antibody Response to the Furin Cleavable Twenty-Seven Amino Acid Peptide (p27) of the Fusion Protein in Respiratory Syncytial Virus (RSV) Infected Adult Hematopoietic Cell Transplant (HCT) RecipientsAuthorYe, X;Cabral de Rezende, W;Iwuchukwu, O;Avadhanula, V;Ferlic-Stark, L;Patel, K;Piedra, F;Shah, D;Chemaly, R;Piedra, P;Year2020JournalVaccinesApplicationElisaFoldedExpand
- Active immunoprophylaxis with a synthetic DNA-encoded monoclonal anti-respiratory syncytial virus scFv-Fc fusion protein confers protection against infection and durable activityAuthorSchultheis, K;Pugh, HM;Oh, J;Nguyen, J;Yung, B;Reed, C;Cooch, N;Chen, J;Yan, J;Muthumani, K;Humeau, LM;Weiner, DB;Broderick, KE;Smith, TRF;Year2020JournalHum Vaccin ImmunotherApplicationElisaPubMed ID: 32544376FoldedExpand
If you couldn"t find the specific citation, you can:
- Find All Citations
- Submit a CitationGet a Publication Reward
- Leave Us a Message
E.coli protein expression service
Mammalian transient protein expression service
Baculovirus-insect expression service
Stable cell line development service (CHO / HEK293)
品牌介绍
北京义翘神州科技股份有限公司(Sino Biological Inc.)是一家从事生物试剂研发、生产、销售并提供技术服务的生物科技公司,主要业务包括重组蛋白、抗体、基因和培养基等产品,以及重组蛋白、抗体的开发和生物分析检测等服务。义翘神州为全球的药品研发企业和生命科学研究机构提供高质量的生物试剂产品和高水平的技术服务。公司目前生产和销售的现货产品种类超过 4.6 万种,其中重组蛋白约 6,000 种,包括超过 3,800 种人源细胞表达重组蛋白产品,能够全面满足客户对于最接近人体天然蛋白结构和性质的重组蛋白需求;公司还能提供约 12,000 种抗体,其中单克隆抗体数量约 4,600 种,能够覆盖生命科学研究的多个领域,为分子生物学、细胞生物学、免疫学、发育生物学、干细胞研究等基础科研方向和创新药物研发提供「一站式」生物试剂产品和技术服务。义翘神州的客户涵盖大学、科研院所、医药研发企业等国内外各类生物研发单位。目前公司已经在美国、欧洲建立了子公司,已成为生物试剂行业国内领先的科技公司之一。
联络我们